Impact of Text Messages to Promote Secondary Prevention After Acute Coronary Syndrome (IMPACS)
Impact of a Mobile Phone Text Messages Intervention on the Secondary Prevention of Cardiovascular Events After Acute Coronary Syndrome
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Purpose of the trial: The purpose of the study is to evaluate the effectiveness of automated mobile phone text message-based intervention for secondary prevention after acute coronary syndrome hospitalization.
Trial design: Two-parallel arm, single-blind, block randomization.
Primary endpoint: The proportion achieving guideline levels of modifiable risk factors (LDL-C <70mg/dL, blood pressure <140/90 mm Hg, exercising regularly [≥5 d/wk × 30minutes of moderate exercise per session], nonsmoker status, and BMI <25). The investigators prespecified in the statistical analysis plan the efficacy variable of proportion achieving combined risk factor control (achieving risk factor targets in 4 or more of the 5 modifiable risk factors listed above) as a measure of a multiple risk factor effect.
Secondary endpoints: The plasma LDL-C level at 6 months, Level of physical activity, Blood Pressure, Medication adherence measured via Morisky scale, Proportion of non-smokers, Body mass index (BMI), Rates death and hospitalization up to 6 months.
Duration of follow-up: 6 months
Trial treatment:
Intervention: The treatment group will receive the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the text-messaging intervention. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living habits texts. There will be four streams: one for patients who are non-smokers and are free of diabetes; one for current/recent smokers; one for diabetic patients; and one for smoker and diabetic patients. Texts will be sent out 4 times per week for 180 days. All participants in the same stream will receive the same texts in the same order.
Control: The usual care group will receive standard discharge treatment, instructions, and information for patients with acute coronary syndrome. The participants will also receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
Expected sample size, enrollment and expected number of centers:
Sample size = 160 Recruitment start date: November, 2017 Recruitment end date: May, 2019 Follow-up end date: November, 2019 Number of centers: 1
Statistical considerations:
- Intention to treat analysis
- The trial has >90% power (2 sided alpha = 0.05) to detect 15% difference in achieving risk factor targets in 4 or more of the 5 modifiable risk factors listed.
Tipo di studio
Iscrizione (Anticipato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
MG
-
Belo Horizonte, MG, Brasile, 30575210
- Reclutamento
- Luiz Guilherme Passaglia
-
Contatto:
- Luiz G Passaglia, master's
- Numero di telefono: 3199038674
- Email: lg.passaglia@uol.com.br
-
Investigatore principale:
- Luiz G Passaglia, M.D.
-
Investigatore principale:
- Antônio LP Ribeiro, M.D., Ph.D
-
Sub-investigatore:
- Luisa CC Brant, M.D., Ph.D
-
Sub-investigatore:
- Bruno R Nascimento, M.D., Ph.D.
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Consecutive patients who have been hospitalized at the UFMG's University Hospital with primary or secondary diagnosis of Acute Coronary Syndrome and are discharged for outpatient follow-up;
- Age ≥ 18 years, of both sexes;
- Patients who are able to receive text messages by their own mobile phone.
Exclusion Criteria:
- Refusal or inability to sign the Informed Consent.
- Complete illiteracy.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Experimental
Automated semi-personalized mobile phone text message-based intervention for secondary prevention plus usual care.
|
The treatment group will receive the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the text-messaging intervention.
The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living habits texts.
There will be four streams: one for patients who are non-smokers and are free of diabetes; one for current/recent smokers; one for diabetic patients; and one for smoker and diabetic patients.
Texts will be sent out 4 times per week for 180 days.
All participants in the same stream will receive the same texts in the same order.
The usual care group will receive standard discharge treatment, instructions, and information for patients with acute coronary syndrome.
They will also receive simple and short text messages related to the importance of trial participation.
|
|
Nessun intervento: No Intervention
Usual Care
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Escore of combined risk factor control
Lasso di tempo: 6 months
|
The proportion achieving guideline levels of modifiable risk factors (LDL-C <77mg/dL, blood pressure <140/90 mm Hg, exercising regularly [≥5 d/wk × 30minutes of moderate exercise per session], nonsmoker status, and BMI <25).
We prespecified in the statistical analysis plan the efficacy variable of proportion achieving combined risk factor control (achieving risk factor targets in 4 or more of the 5 modifiable risk factors listed above) as a measure of a multiple risk factor effect
|
6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Plasma LDL-C level
Lasso di tempo: 6 months
|
Fasting blood sample
|
6 months
|
|
Level of physical activity (measured via
Lasso di tempo: 6 months
|
Measured by research blinded to treatment allocation - The level of physical activity will be mensured by the International Physical Activity Questionnaire Short Form (IPAQ-SF) and it will be validated in one-fifth of the participants by using accelerometers
|
6 months
|
|
Blood Pressure
Lasso di tempo: 6 months
|
Measured by research blinded to treatment allocation - 3 resting, sitting digital recordings, mean of last 2 readings
|
6 months
|
|
Proportion of non-smokers
Lasso di tempo: 6 months
|
Measured by research blinded to treatment allocation - Self-reported smoking / quitting attempts will be confirmed with a Carbon Monoxide Meter Breath Test
|
6 months
|
|
Body mass index (BMI)
Lasso di tempo: 6 months
|
Measured by research blinded to treatment allocation
|
6 months
|
|
Medication adherence (measured via "Medida de adesão aos tratamentos" - MAT)
Lasso di tempo: 6 months
|
Measured by research blinded to treatment allocation It is an instrument composed of seven items that evaluate the behavior of the individual in relation to daily use of medicines.
The answers are obtained by means of a six-point ordinal scale that varies from always (1) to never (6).
The values obtained with the answers to the seven items are summed and divided by the number of items (values vary from 1 to 6).
Subsequently, values 5 and 6 are computed as one (adherent) and the others are computed as zero (non-adherent).
|
6 months
|
|
Death from any cause
Lasso di tempo: 6 months
|
Medical records and database
|
6 months
|
|
Rehospitalization
Lasso di tempo: 6 months
|
Self-report, medical records and database
|
6 months
|
|
Cardiovascular death
Lasso di tempo: 6 months
|
Medical records and database
|
6 months
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CEP1.883.227
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .